Coagulation cascade and fibrin network

The coagulation proteins and fibrin network represent the integrated biochemical system responsible for maintaining hemostasis and preventing blood loss after vascular injury (StatPearls, 2023). This network operates through a cascade of proteolytic activations where inactive zymogens are converted into active serine proteases, ultimately leading to the generation of thrombin (PubMed, 2017). Thrombin then catalyzes the conversion of soluble fibrinogen into insoluble fibrin strands, which polymerize to form a stable meshwork that reinforces the primary platelet plug (NIH, 2022). The network is tightly regulated by natural anticoagulants like protein C, protein S, and antithrombin to prevent systemic clotting (PubMed, 2021). Pathological overactivation of this system can lead to life-threatening thrombotic events such as myocardial infarction, deep vein thrombosis, or stroke (StatPearls, 2023). Conversely, deficiencies in specific proteins within the network, such as Factor VIII or IX, result in bleeding disorders like hemophilia (NIH, 2022). Therapeutic strategies targeting this network include anticoagulants that inhibit clot formation, such as direct factor Xa inhibitors or thrombin inhibitors (PubMed, 2021). Additionally, thrombolytic agents are used to dissolve existing fibrin structures in acute settings like ischemic stroke (StatPearls, 2023). Monitoring the efficacy and safety of these interventions often requires laboratory tests like the International Normalized Ratio (INR) or activated partial thromboplastin time (aPTT) (PubMed, 2017). Overall, this network is a critical therapeutic focus for managing both thrombotic and hemorrhagic conditions.

Other names

Blood clotting systemHemostatic systemCoagulation pathwayFibrinolytic systemCoagulation proteins

Drugs targeting this network function through several mechanisms: direct inhibition of specific proteases like Factor Xa or Thrombin; indirect inhibition via antithrombin III activation; antagonism of Vitamin K to prevent the synthesis of functional factors II, VII, IX, and X; or the activation of plasminogen to catalyze the breakdown of the fibrin mesh (StatPearls, 2023; PubMed, 2021).